Piramal Pharma Limited (PPLPHARMA) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Piramal Pharma enters Q1 FY27 navigating a complex global landscape, with the company’s CDMO, Hospital Generics, and Consumer Healthcare segments adjusting to shifting biopharma funding and supply chain volatility. Investors are closely watching the maiden quarterly contribution of the newly acquired Kenalog portfolio and whether the company's operating leverage can sustain the margin expansion trajectory guided for the full year.

Piramal Pharma Limited Q1 Results Date and Time

The board will meet on 29 July 2026 to consider unaudited standalone and consolidated results for Q1 FY27.

What to expect from Piramal Pharma Limited's Q1 FY27 results

Piramal Pharma's revenue growth for Q1 FY27 is expected to benefit from a favourable INR depreciation of approximately 12-14% against the USD compared to Q1 FY26, alongside the first full quarter contribution from the Kenalog acquisition which targets annualized revenues of US$30-40 Mn. While Q1 is seasonally the company's weakest quarter, the CDMO business is expected to reflect the strong RFP momentum that began in H2 FY26, supported by a pipeline of 145 projects including 31 in Phase III. EBITDA margins are likely to show expansion over the 8.5% reported in Q1 FY26, driven by operating leverage and the higher-margin profile of the CHG segment, though they may remain below the 18.4% seen in the seasonally stronger Q4 FY26. Management has guided for FY27 EBITDA to grow faster than revenue, making the margin trajectory in this first quarter a critical indicator of operational progress. The company’s net debt/EBITDA ratio of 3.6x as of March 2026 remains a focus, with ongoing capex for the Lexington expansion expected to keep leverage elevated in the near term.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring the company's progress against its FY27 targets during the seasonally quiet first quarter.

• Revenue growth: Targeting early to mid-teens for FY27
• EBITDA growth: Expected to outpace revenue growth for FY27
• PAT: Guided to achieve positive growth for FY27

Kenalog® Revenue Contribution: Assessing the integration of the brand acquired from Bristol Myers Squibb effective 1 April 2026.

• First full quarter of ownership in Q1 FY27
• Annualized revenue target of US$30 Mn to US$40 Mn

CDMO Order Inflow Trajectory: Evaluating demand signals linked to US biopharma funding recovery.

• RFP momentum: Assessing if strong H2 FY26 trends continued into Q1
• Pipeline: Progress updates on 145 total projects including 31 in Phase III

Sevoflurane RoW and US Market Share: Tracking competitive dynamics in inhalation anesthesia.

• Digwal regulatory approvals for ex-US markets: Status update
• US market share: Maintaining the 47% share achieved as of March 2026

Risks and headwinds to monitor: Management-flagged operational and regulatory considerations.

• West Asia supply chain: Caution regarding potential working capital pressure and freight costs
• Institutional sentiment: Monitoring impact of HDFC Mutual Fund's 2% stake sale on 14 July 2026